BridgeBio Oncology Therapeutics, Inc. (BBOT) stock
BBOTNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.80−0.14 (-6.96%)
Close on Nov 18, 2026Market cap $144.72MP/E –Yield –
BridgeBio Oncology Therapeutics gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
No gross profit figures for BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?